HRP20050744A2 - 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis - Google Patents

4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis

Info

Publication number
HRP20050744A2
HRP20050744A2 HR20050744A HRP20050744A HRP20050744A2 HR P20050744 A2 HRP20050744 A2 HR P20050744A2 HR 20050744 A HR20050744 A HR 20050744A HR P20050744 A HRP20050744 A HR P20050744A HR P20050744 A2 HRP20050744 A2 HR P20050744A2
Authority
HR
Croatia
Prior art keywords
ylmethoxy
oxazol
cyclohexyloxy
atherosclerosis
phenyl
Prior art date
Application number
HR20050744A
Other languages
English (en)
Inventor
Stapper Christian
Keil Stefanie
Glombik Heiner
Falk Eugen
Goerlitzer Jochen
Gretzke Dirk
Schaefer Hans-Ludwig
Wendler Wolfgang
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HRP20050744A2 publication Critical patent/HRP20050744A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Izum se odnosi na derivate alkanskih kiselina supstituirane s aril-cikloalkilom, kao i njihove fiziološki podnošljive soli i fiziološki funkcionalne derivate. Opisani su spojevi formule (I),-u kojoj radikali imaju navedena značenja, kao i njihove fiziološki podnošljive soli i postupci za njihovu proizvodnju. Ovi spojevi su prikladni npr. za liječenje i/ili prevenciju poremećaja metabolizma masne kiselina i poremećaja trošenja glukoze, kao i poremećaja u kojima ima ulogu inzulinska rezistencija.
HR20050744A 2003-02-27 2005-08-26 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis HRP20050744A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001586 WO2004076428A1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number Publication Date
HRP20050744A2 true HRP20050744A2 (en) 2006-09-30

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
HR20050743A HRP20050743A2 (en) 2003-02-27 2005-08-26 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
HR20050744A HRP20050744A2 (en) 2003-02-27 2005-08-26 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis
HR20050742A HRP20050742A2 (en) 2003-02-27 2005-08-26 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HR20050743A HRP20050743A2 (en) 2003-02-27 2005-08-26 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20050742A HRP20050742A2 (en) 2003-02-27 2005-08-26 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Country Status (34)

Country Link
US (5) US7365084B2 (hr)
EP (3) EP1599455B1 (hr)
JP (3) JP2006519199A (hr)
KR (3) KR20050106461A (hr)
CN (3) CN100398526C (hr)
AR (3) AR043427A1 (hr)
AT (3) ATE435217T1 (hr)
AU (3) AU2004215673B2 (hr)
BR (3) BRPI0407758A (hr)
CA (3) CA2516620A1 (hr)
CL (2) CL2004000392A1 (hr)
CO (2) CO5690578A2 (hr)
DE (4) DE10308355A1 (hr)
DK (3) DK1599452T3 (hr)
EC (2) ECSP055986A (hr)
ES (3) ES2326418T3 (hr)
HR (3) HRP20050743A2 (hr)
IL (2) IL170314A (hr)
MA (3) MA27737A1 (hr)
MX (3) MXPA05008995A (hr)
NO (3) NO20054398L (hr)
OA (2) OA13034A (hr)
PA (1) PA8596801A1 (hr)
PE (3) PE20040959A1 (hr)
PL (3) PL378437A1 (hr)
PT (3) PT1599453E (hr)
RS (1) RS20050594A (hr)
RU (3) RU2005129995A (hr)
SA (1) SA04250153A (hr)
TN (2) TNSN05206A1 (hr)
TW (3) TW200510352A (hr)
UY (2) UY28210A1 (hr)
WO (3) WO2004076428A1 (hr)
ZA (2) ZA200505765B (hr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
BRPI0621960A2 (pt) 2006-08-10 2011-12-27 Wood One Co Ltd composiÇço hipoglicÊmica contendo derivado da casca de acÁcia
US8481778B2 (en) 2007-08-16 2013-07-09 Solvay (Societe Anonyme) Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
KR101613745B1 (ko) 2008-02-29 2016-04-19 닛산 가가쿠 고교 가부시키 가이샤 티오펜 화합물 및 그 중간체의 제조 방법
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
KR102499050B1 (ko) 2017-12-13 2023-02-14 캐논 가부시끼가이샤 카트리지
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
BR9707003A (pt) 1996-01-17 1999-07-20 Novo Nordisk As Composto processos para preparar o mesmo para tratamento ou de prevenção de doenças do sistema endócrino e para a manufatura de medicamento coposção farmacêutica e utilização de um composto
WO1997041097A2 (en) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
EP1826216A1 (en) 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1 derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
CA2294830A1 (en) 1997-07-16 1999-01-28 John Bondo Hansen Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
WO1999046232A1 (fr) * 1998-03-10 1999-09-16 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique et medicaments contenant ces derives comme principe actif
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
WO2000012491A1 (fr) * 1998-08-27 2000-03-09 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique et medicaments dont ils sont le principe actif
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
AU3956900A (en) 1999-04-16 2000-11-02 Boehringer Ingelheim International Gmbh Substituted imidazoles, their preparation and use
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
JP2002543065A (ja) * 1999-04-28 2002-12-17 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｐ受容体リガンドとしてのトリアリール酸誘導体
JP2002543200A (ja) 1999-04-30 2002-12-17 ニューロゲン コーポレイション ９Ｈ−ピリミド［４、５−ｂ］インドール誘導体：ＣＲＦ１特異性リガンド
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
WO2001009111A1 (en) 1999-07-29 2001-02-08 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
CA2383781A1 (en) 1999-09-01 2001-03-08 Aventis Pharma Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
RU2268880C2 (ru) 1999-12-03 2006-01-27 Астразенека Аб Кристаллическая форма (s)-2-этокси-3-[4-(2-{4-метансульфонилоксифенил}этокси)фенил]пропановой кислоты
DE60137216D1 (de) 2000-03-31 2009-02-12 Prosidion Ltd Verbesserung der aktivität der inselzellen bei diabetes mellitus und dessen prävention
CZ20023502A3 (cs) 2000-04-25 2003-06-18 Kyorin Pharmaceutical Co., Ltd. Nová stabilní krystalická forma thiazolidionového derivátu a způsob jeho přípravy
CN1430603A (zh) 2000-04-28 2003-07-16 旭化成株式会社 新型双环化合物
ATE310728T1 (de) 2000-05-11 2005-12-15 Bristol Myers Squibb Co Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
AU6497701A (en) 2000-05-30 2001-12-11 Merck & Co Inc Melanocortin receptor agonists
NZ523034A (en) 2000-06-09 2004-07-30 Aventis Pharma Gmbh Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
ES2288982T3 (es) 2000-08-23 2008-02-01 Eli Lilly And Company Derivados de acido oxazolil-ariloxiacetico y su uso como agonistas ppar.
SK1872003A3 (en) * 2000-08-23 2003-07-01 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
AU2002216097B2 (en) 2000-12-21 2006-09-07 Sanofi-Aventis Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
PL207798B1 (pl) * 2000-12-25 2011-02-28 Ono Pharmaceutical Co Pochodne dihydronaftalenu i zawierające je regulatory receptorów aktywowanych przez proliferatory peroksysomów, takie jak agonista PPAR, środek hipoglikemiczny i/lub hipolipidemiczny, środek do podwyższania poziomu cholesterolu HDL i/lub obniżania poziomu LDL i/lub VLDL oraz środki do zapobiegania i/lub leczenia chorób związanych z zaburzeniami metabolicznymi
MXPA03007284A (es) * 2001-02-15 2003-12-04 Pfizer Prod Inc Agonistas de receptor activador del proliferador de peroxisomas.
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
US7282501B2 (en) * 2001-06-07 2007-10-16 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (PPAR)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
PT1425014E (pt) 2001-08-31 2007-03-30 Sanofi Aventis Deutschland Derivados diarilcicloalquilo, processo para a sua preparação como activadores de ppar
EP1474385B1 (en) 2002-02-05 2009-06-10 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
ES2326418T3 (es) 2009-10-09
WO2004076428A1 (de) 2004-09-10
RU2005129995A (ru) 2006-01-27
US20080015238A1 (en) 2008-01-17
EP1599453A1 (de) 2005-11-30
PL378130A1 (pl) 2006-03-06
TW200510352A (en) 2005-03-16
CA2517381A1 (en) 2004-09-10
ES2287700T3 (es) 2007-12-16
ES2329366T3 (es) 2009-11-25
TW200500349A (en) 2005-01-01
CO5690580A2 (es) 2006-10-31
ZA200505765B (en) 2006-05-31
UY28209A1 (es) 2004-09-30
RU2005130002A (ru) 2006-01-27
US20050215596A1 (en) 2005-09-29
NO20054396L (no) 2005-11-11
EP1599455A1 (de) 2005-11-30
MA27737A1 (fr) 2006-02-01
US7872034B2 (en) 2011-01-18
JP2006519193A (ja) 2006-08-24
RS20050594A (en) 2007-12-31
PT1599455E (pt) 2009-09-29
ECSP055985A (es) 2006-01-16
NO20054398L (no) 2005-11-02
AU2004215672A1 (en) 2004-09-10
AR043432A1 (es) 2005-07-27
PT1599452E (pt) 2007-09-12
RU2005129992A (ru) 2006-02-10
US7335671B2 (en) 2008-02-26
BRPI0407758A (pt) 2006-02-14
SA04250153A (ar) 2005-12-03
OA13035A (en) 2006-11-10
TW200508210A (en) 2005-03-01
ATE435217T1 (de) 2009-07-15
AU2004215672B2 (en) 2010-01-07
AU2004215673A1 (en) 2004-09-10
ECSP055986A (es) 2006-01-16
US20050101637A1 (en) 2005-05-12
OA13034A (en) 2006-11-10
AU2004215677B2 (en) 2010-01-07
ATE430738T1 (de) 2009-05-15
CN100439345C (zh) 2008-12-03
WO2004076426A1 (de) 2004-09-10
US7259177B2 (en) 2007-08-21
NO20054396D0 (no) 2005-09-22
WO2004076427A1 (de) 2004-09-10
EP1599453B1 (de) 2009-05-06
CN100398526C (zh) 2008-07-02
AR043433A1 (es) 2005-07-27
KR20050106462A (ko) 2005-11-09
ATE365159T1 (de) 2007-07-15
DE502004009453D1 (de) 2009-06-18
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
DE502004009690D1 (de) 2009-08-13
PE20050293A1 (es) 2005-05-24
CL2004000392A1 (es) 2005-04-22
KR20050105492A (ko) 2005-11-04
HRP20050742A2 (en) 2006-09-30
DE10308355A1 (de) 2004-12-23
BRPI0407907A (pt) 2006-02-14
KR20050106461A (ko) 2005-11-09
DK1599452T3 (da) 2007-10-01
US20040209920A1 (en) 2004-10-21
CN1753879A (zh) 2006-03-29
MXPA05008951A (es) 2005-11-04
CL2004000391A1 (es) 2005-01-07
BRPI0407814A (pt) 2006-02-14
CA2517386A1 (en) 2004-09-10
CN1756748A (zh) 2006-04-05
CN100439347C (zh) 2008-12-03
DK1599453T3 (da) 2009-08-24
TNSN05206A1 (en) 2007-06-11
PE20040959A1 (es) 2005-01-17
PT1599453E (pt) 2009-07-14
NO20054398D0 (no) 2005-09-22
US7365084B2 (en) 2008-04-29
MA27736A1 (fr) 2006-02-01
PL377735A1 (pl) 2006-02-20
ZA200505768B (en) 2005-11-23
IL170314A (en) 2010-11-30
JP2006519194A (ja) 2006-08-24
JP2006519199A (ja) 2006-08-24
US20080167354A1 (en) 2008-07-10
CN1753881A (zh) 2006-03-29
CA2516620A1 (en) 2004-09-10
CO5690578A2 (es) 2006-10-31
EP1599452A1 (de) 2005-11-30
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
DE502004004139D1 (de) 2007-08-02
AU2004215677A1 (en) 2004-09-10
PE20050292A1 (es) 2005-05-24
NO20054408D0 (no) 2005-09-22
UY28210A1 (es) 2004-09-30
MXPA05008988A (es) 2005-10-18
EP1599452B1 (de) 2007-06-20
PL378437A1 (pl) 2006-04-03
MA27742A1 (fr) 2006-02-01
TNSN05204A1 (en) 2007-06-11
AR043427A1 (es) 2005-07-27
EP1599455B1 (de) 2009-07-01
DK1599455T3 (da) 2009-11-09
MXPA05008995A (es) 2005-10-18
AU2004215673B2 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
HRP20050744A2 (en) 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis
ATE534650T1 (de) Neue cyanothiazolide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
HRP20050710A2 (en) Substituted n-arylheterocycles, method for production and use thereof as medicaments
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MA27134A1 (fr) Derives diarylcycloalkyle, leur procede de preparation et leur utilisation en tant qu'activateurs des ppar
WO2005080313A3 (en) Sulfonamide derivatives for the treatment of diseases
DE602005010401D1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
IL176915A0 (en) Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
MA32455B1 (fr) Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1
RS20050744A (en) Benzopyran compounds useful for treating inflammatory conditions
JO2449B1 (en) Thiosol derivatives - benziazothiazole dioxide, methods of preparation and use.
HRP20050715A2 (en) Substituted 3-(benzoylureido)-thiophene derivatives, method for the production and use thereof
DE502005007850D1 (de) Substituierte cyclohexyl-1,4-diamin-derivate
HRP20050741A2 (en) 1,3-substituted cycloalkyl containing acidic, mainly heterocyclic groups, corresponding production method and use of said derivatives as medicaments
EA201001408A1 (ru) Производные пиразинона как стимуляторы секреции инсулина, способы их получения и их применение для лечения диабетов
HRP20050739A2 (en) Cycloalkyl-substituted alkanoic acid derivatives, methods for the production thereof, and use thereof as a medicament
WO2002050058A8 (en) Crystal forms of 6-[(4-chloro-phenyl) -hydroxy-(-3-methyl- 3h-imidaol-4-yl) -methyl] -4-(3-ethynyl-phenyl) -1-methyl-1h- quinolin-2-one, 2,3- dihydroxybutanedioate salts and method of production
CO5690587A2 (es) Derivados de acido bensoilureidopiridil-piperidin-y pirrolidin carboxilico sustituido, metodo para su produccion y su uso
BRPI0411087A (pt) aperfeiçoamentos em ou relacionados a compostos orgánicos
DK1706121T3 (da) Dk/ep
WO2003089577A3 (en) Antihelminthic anthraquinones and method of use thereof
NO20053876L (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20051229

Year of fee payment: 3

A1OB Publication of a patent application
OBST Application withdrawn